n-3 @entity1474 for the prevention of XXXX recurrence after electrical cardioversion of chronic persistent @entity955 : a randomized, double-blind, multicentre study.

@entity1 @entity5204 @entity1474 @entity955 @entity943
AIMS: Persistent @entity955 ( @entity955 ) often recurs after direct current electrical cardioversion (ECV). As several experimental and clinical studies suggest that n-3 @entity1474 ( @entity5204 ) may have antiarrhythmic properties even at the atrial level, we aimed to evaluate whether oral supplementation with @entity5204 , in addition to conventional antiarrhythmic drugs, could reduce the recurrence rate of the @entity943 after ECV of persistent @entity955 . METHODS AND RESULTS: Two hundred and four @entity1 (mean age 69.3 years, 33% females) with persistent @entity955 were randomly assigned to receive 3 g/day of @entity5204 until ECV and 2 g/day thereafter (104 @entity1 ) or placebo (100 @entity1 ) for 6 months, beginning at least 1 week before ECV. Selection of conventional antiarrhythmic prophylaxis was left to local medical advice. The cardiac rhythm was assessed by both trans-telephonic monitoring and clinical visits. Primary end-point was the recurrence rate of @entity955 . Sinus rhythm was restored, either spontaneously or after ECV, in 187 @entity1 (91.7%); 95 @entity1 (91.4%) on @entity5204 and 92 @entity1 (92.0%) on placebo (P=not significant). @entity955 relapsed in 56 (58.9%) of the @entity5204 @entity1 and in 47 (51.1%) of the placebo @entity1 (P=0.28). The mean time to @entity955 recurrence was 83  8 days in the @entity5204 group and 106  9 days in the placebo group (P=0.29). CONCLUSION: Our results do not support the hypothesis that, in @entity1 undergoing ECV of chronic persistent @entity955 , supplementation with @entity5204 in addition to the usual antiarrhythmic treatment reduces recurrent @entity955 .
